Nova Eye Medical Limited (ASX:EYE)

Market Cap	33.47M -1.8%
Revenue (ttm)	33.05M +26.6%
Net Income	-7.03M
EPS	-0.03
Shares Out	284.84M
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	254,565
Open	0.1150
Previous Close	0.1200
Day's Range	0.1150 - 0.1200
52-Week Range	0.1000 - 0.2050
Beta	0.92
Analysts	Buy
Price Target	0.38 (+224.79%)
Earnings Date	Aug 26, 2026

About Hatton National Bank

Nova Eye Medical Limited designs, develops, manufactures, markets, and sells surgical devices for the treatment of glaucoma in Australia, the United States, Europe, the Asia Pacific, and internationally. It also engaged in the commercialisation of the subthreshold nano-pulse ophthalmic laser; 2RT, a proprietary laser technology to treat patients in early and intermediate age-related macular degeneration for the treatment of retinal disease. The company offers iTrack, a glaucoma surgical device to reduce intraocular pressure in patients glaucoma...

• Industry: Medical Devices
• Sector: Healthcare
• Founded: 1970
• Employees: 301
• Stock Exchange: Australian Securities Exchange
• Ticker Symbol: EYE

Financial Performance

In fiscal year 2025, Nova Eye Medical's revenue was 29.27 million, an increase of 25.47% compared to the previous year's 23.33 million. Losses were -9.06 million, 3.06% more than in 2024.

Analyst Summary

According to 2 analysts, the average rating for EYE stock is "Buy." The 12-month stock price target is $0.38, which is an increase of 224.79% from the latest price.

Price Target

$0.38

(224.79% upside)

Analyst Consensus: Buy